Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our ...

Researchers from the National University of Singapore (NUS) have pioneered a new catalytic transformation that converts ...

E1s and E2s first work generically across the cell to activate and prepare ubiquitin for attachment. E3 ligases then ensure that the tag is added to the right protein; as such, hundreds of specific ...

Researchers have developed a powerful computational tool, named iDOMO, to improve the prediction of drug synergy and accelerate the development of combination therapies for complex diseases. The study ...

Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company utilizing artificial intelligence to expedite drug ...

Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 ...

Precise calculations of binding free energy are pivotal in reducing the high costs and inefficiencies of drug discovery. A recent study presents PairMap, an innovative computational tool that ...

The company will use the seed capital to develop clinical programs, A.I. platforms and its drug candidate pipeline. Manas AI will host its systems on Microsoft (MSFT)’s Azure cloud computing ...